English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduRadiation is an effective treatment for prostate cancer. Ronald D. Ennis, MD,Professor and Vice Chair of Network Integration and Quality, Department of Radiation Oncology at Rutgers Cancer Institute, along with Lara Hathout, MD, FRCPC, radiation oncologist and director of Brachytherapy at Rutgers Cancer Institute and associate Professor of radiation oncology at Rutgers Robert Wood Johnson Medical School share more
Tag: prostate cancer
Henry Ford Health is First in the World to Offer Latest Advancement in MR-Guided Radiation Therapy
Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.
UCSF Prostate Cancer Specialist Inducted into Annual Class of “Giants of Cancer Care”
Eric Small, MD, has been announced as one of the winners of the 10th annual Giants of Cancer Care® awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.
New Combined Therapy Helps Extend Lives of Men With Prostate Cancer
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.
Zulu Social Aid and Pleasure Club Presents Men’s Health Fair, Sponsored by Ochsner Xavier Institute of Health Equity and Research
Zulu Social Aid and Pleasure Club Presents Men’s Health Fair, Sponsored by Ochsner Xavier Institute of Health Equity and Research.
Researchers uncover how tumors circumvent prostate cancer therapy, identify promising treatment strategy
A Cleveland Clinic-led research team uncovered how tumors circumvent prostate cancer therapy and identified a promising new strategy for treatment. Findings were published in Proceedings of the National Academy of Sciences (PNAS). Antiandrogen strategies remain the backbone for advanced prostate…
Study Finds Wide Variations in Prostate Cancer Risk Within Hispanic Subgroups
Research underscores the need to subdivide Hispanics and other racial and ethnic groups to fully understand actual disparities. Brandon A. Mahal, M.D. In a massive study, clinical researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School…
TipSheet: Research Highlights Potential Benefits of Vibrators on Women’s Pelvic Health
Cedars-Sinai urology experts will present their latest advances in urologic medicine at the annual scientific meeting of the American Urological Association (AUA) in New Orleans May 13-16, 2022. Among over 2,200 abstracts, one by Alexandra Dubinskaya, MD, a female pelvic medicine and reconstructive surgery (FPMRS) specialist—Is It Time for FPMRS to Prescribe Vibrators?—was selected to be included in the 117th AUA press session on May 13, 2022, at 9 a.m. CT.
Henry Ford Health First in Michigan to Offer Robotic High-Intensity Focused Ultrasound for Prostate Cancer
Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer. This non-surgical treatment option spares surrounding healthy tissue, while allowing for a quicker treatment time and recovery for the patient.
April Research Highlights
This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.
Yale Cancer Center Study Shows Rates of PSA Testing for Prostate Cancer Increased After Revised National Guidelines
In a large study led by Yale Cancer Center, more men received a prostate-specific antigen or PSA test to detect prostate cancer following revisions to the recommendation by the U.S. Preventative Services Task Force on screening. The results also showed significant increases in PSA testing among older men, a group for whom screening is not routinely recommended.
New drug delivery could significantly improve treatment outcomes for localised prostate cancer
Researchers have developed a new treatment to be used in combination with radiotherapy that could significantly improve treatment outcomes for men with locally advanced prostate cancer.
New strategy against treatment-resistant prostate cancer identified
A new study from Washington University School of Medicine in St. Louis has identified an RNA molecule that suppresses prostate tumors. The scientists found that prostate cancers develop ways to shut down this RNA molecule to allow themselves to grow.
NCCN Announces Funding for Prostate Cancer Research Projects, in Collaboration with Pfizer and Astellas
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on the use of enzalutamide in treating people with prostate cancer.
Studies Find B7-H3 Protein a Novel, Promising Target for Prostate Cancer Treatments
The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center. The studies were presented recently at the European Society for Medical Oncology (ESMO) 2021 Conference.
Cleveland Clinic Study Links Gut Microbiome and Aggressive Prostate Cancer
Cleveland Clinic researchers have shown for the first time that diet-associated molecules in the gut are associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. Findings from the study were published in Cancer Epidemiology, Biomarkers & Prevention.
The Medical Minute: Prostate cancer risks in African American men
African American men are at the highest risk for both developing and dying from prostate cancer. It is essential that this population take preventative measures and seek appropriate treatment if diagnosed.
Genetic biomarker test predicts recurrence and survival outcomes for men with high-risk prostate cancer
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected from three large, randomized clinical trials, indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Shortened course of radiation therapy offers similar long-term side effects following prostate removal surgery
Using fewer—but higher—doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.
New Noninvasive Tests for Colon and Prostate Cancer Presented at the 2021 AACC Annual Scientific Meeting
Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively. Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.
Men should check their genes for prostate cancer risk
As Prostate Cancer Awareness Month comes to a close, researchers want to circulate the message that some gene mutations linked to breast and ovarian cancer are also associated with prostate cancer.
Metastatic prostate cancer comes in two forms, which could guide treatment
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
Yale Cancer Center Study Finds New Drug Combination Shows Clinical Activity for Patients with Prostate Cancer
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer.
Q&A: How a new imaging tool helps to better stage men with prostate cancer
A paper detailing the method that led to the US Food and Drug Administration approval for PSMA PET imaging, which was led by UCLA and UCSF and their nuclear medicine teams, was recently published in JAMA Oncology.
Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment
For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Advancements in Prostate Cancer Treatments are Providing Better Outcomes for Men
Over the last decade, advancements have been made in the diagnosis and treatment of prostate cancer that are saving more lives. Tina Mayer, MD, a medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey shares some insight.
Understanding Good Prostate Health for Cancer Prevention
Tina Mayer, MD, medical oncologist in the Prostate Cancer Program at Rutgers Cancer Institute of New Jersey and an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, shares information about prostate health.
MD Anderson Research Highlights for September 8, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts.
UCLA researchers to present on latest research and clinical advancements at American Urological Association Annual Meeting
Physicians and scientists from UCLA will be joining thousands of urology experts on Sept. 10 to Sept. 13 for the virtual American Urological Association (AUA) Annual Meeting.
One-half of patients with low-risk prostate cancer switch from active surveillance to active treatment
Nearly half of men initially managed with active surveillance for “low-risk” prostate cancer transition to definitive treatment – such as surgery or radiation therapy – within a few years after diagnosis, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
Prostate cancer partnership honored for statistical excellence in accelerating therapeutic advances
The Intermediate Clinical Endpoints of Cancer of the Prostate (ICECaP) working group, led by Dana-Farber Cancer Institute researchers, is being honored by the American Statistical Association (ASA) with the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award.
Researchers uncover a way to harness the power of immunotherapy for advanced prostate cancer
Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.
Genomic test could help predict aggressive disease in men newly diagnosed with prostate cancer
A new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of prostate cancer progression.
Mount Sinai researchers develop novel therapy that could be effective in many cancers
New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…
Prostate cancer treatment among black, white patients during pandemic
What The Study Did: This study included 647 patients with untreated nonmetastatic prostate cancer (269 patients during the pandemic and 378 from before the pandemic). During the initial COVID-19 lockdown, only 1% of Black men underwent prostatectomy, while 26% of…
Bidirectional impact of cardiovascular disease, cancer in Blacks focus of new AHA center
Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…
MRI can cut overdiagnoses in prostate-cancer screening by half
Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine ,…
American Society for Radiation Oncology (ASTRO) to host Annual Meeting in Chicago 10/24-27
#ASTRO21 will be the first major medical conference in the city; a curated digital program also will be offered for remote attendees
Anti-androgen therapy can fuel spread of bone tumours in advanced prostate cancer
Miniature 3D bone-like tissue models show effects of anti-androgens
New AI tech for early detection of prostate cancer
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds
Tool helps predicts who will respond best to targeted prostate cancer therapy
New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows
Multimodality care improves treatment outcomes for aggressive prostate cancer
Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study.
Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD
Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as a Professor of Urology, Director of Education and Director of the Precision Prostatectomy Program in the Department of Urology at Icahn Mount Sinai and Center of Excellence for Prostate Cancer at The Tisch Cancer Institute.
Multimodality care improves treatment outcomes for aggressive prostate cancer
FINDINGS Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of…
Reactive oxygen species (ROS): Key components in cancer therapies
The article by Dr. Biswa Mohan Sahoo et al. is published in Anti-Cancer Agents in Medicinal Chemistry, 2021
Study Sheds Light on Persistent Racial Disparities in Prostate Cancer Care in the United States
Black men most likely to benefit from advanced prostate cancer therapies are 11 percent less likely to get them than non-Black men. This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.
Immunotherapy may be effective for subset of prostate cancer
Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that suggest a substantial number of patients with prostate cancer may benefit from immunotherapies.
Immunotherapy may be effective for subset of prostate cancer
Boston – In recent years, cancer immunotherapy has been effective in treating patients with immunogenic, or so-called “hot” tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered…
BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs
In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.
PSMA-targeted radiotracer pinpoints metastatic prostate cancer across anatomic regions
Newly FDA-approved imaging agent now available for patients